These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11552770)

  • 1. Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study.
    Schutz G; Berk M
    Int Clin Psychopharmacol; 2001 Sep; 16(5):275-8. PubMed ID: 11552770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
    Usall J; López-Carrilero R; Iniesta R; Roca M; Caballero M; Rodriguez-Jimenez R; Oliveira C; Bernardo M; Corripio I; Sindreu SD; González Piqueras JC; Felipe AE; Fernandez de Corres B; Ibáñez A; Huerta R;
    J Clin Psychiatry; 2014 Jun; 75(6):608-15. PubMed ID: 25004184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No effects of antidepressants on negative symptoms in schizophrenia.
    Hinkelmann K; Yassouridis A; Kellner M; Jahn H; Wiedemann K; Raedler TJ
    J Clin Psychopharmacol; 2013 Oct; 33(5):686-90. PubMed ID: 23857309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study.
    Poyurovsky M; Faragian S; Fuchs C; Pashinian A
    Isr J Psychiatry Relat Sci; 2009; 46(3):213-20. PubMed ID: 20039523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia.
    Lee MS; Kim YK; Lee SK; Suh KY
    J Clin Psychopharmacol; 1998 Oct; 18(5):399-403. PubMed ID: 9790158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination.
    Poyurovsky M; Fuchs C; Pashinian A; Levi A; Weizman R; Weizman A
    Psychopharmacology (Berl); 2013 Apr; 226(3):615-22. PubMed ID: 23239133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.
    Poyurovsky M; Isaacs I; Fuchs C; Schneidman M; Faragian S; Weizman R; Weizman A
    Am J Psychiatry; 2003 Feb; 160(2):297-302. PubMed ID: 12562576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
    Akhondzadeh S; Safarcherati A; Amini H
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
    Berk M; Ichim C; Brook S
    Int Clin Psychopharmacol; 2001 Mar; 16(2):87-92. PubMed ID: 11236073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of reboxetine on Hamilton Depression Rating Scale factors from randomized, placebo-controlled trials in major depression.
    Ferguson JM; Mendels J; Schwart GE
    Int Clin Psychopharmacol; 2002 Mar; 17(2):45-51. PubMed ID: 11890185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of reboxetine in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial.
    Riahi F; Tehrani-Doost M; Shahrivar Z; Alaghband-Rad J
    Hum Psychopharmacol; 2010 Nov; 25(7-8):570-6. PubMed ID: 21312292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.
    Müller N; Schwarz MJ; Dehning S; Douhe A; Cerovecki A; Goldstein-Müller B; Spellmann I; Hetzel G; Maino K; Kleindienst N; Möller HJ; Arolt V; Riedel M
    Mol Psychiatry; 2006 Jul; 11(7):680-4. PubMed ID: 16491133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.
    Arvanitis LA; Miller BG
    Biol Psychiatry; 1997 Aug; 42(4):233-46. PubMed ID: 9270900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clonidine plus haloperidol in the treatment of schizophrenia/psychosis.
    Maas JW; Miller AL; Tekell JL; Funderburg L; Silva JA; True J; Velligan D; Berman N; Bowden CL
    J Clin Psychopharmacol; 1995 Oct; 15(5):361-4. PubMed ID: 8830068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.
    Tollefson GD; Sanger TM; Beasley CM; Tran PV
    Biol Psychiatry; 1998 Jun; 43(11):803-10. PubMed ID: 9611669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antidepressant efficacy of reboxetine in patients with severe depression.
    Montgomery S; Ferguson JM; Schwartz GE
    J Clin Psychopharmacol; 2003 Feb; 23(1):45-50. PubMed ID: 12544375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis.
    Singh SP; Singh V; Kar N; Chan K
    Br J Psychiatry; 2010 Sep; 197(3):174-9. PubMed ID: 20807960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
    Khodaie-Ardakani MR; Seddighi S; Modabbernia A; Rezaei F; Salehi B; Ashrafi M; Shams-Alizadeh N; Mohammad-Karimi M; Esfandiari GR; Hajiaghaee R; Akhondzadeh S
    J Psychiatr Res; 2013 Apr; 47(4):472-8. PubMed ID: 23375406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
    Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
    J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison.
    Kane JM; Marder SR; Schooler NR; Wirshing WC; Umbricht D; Baker RW; Wirshing DA; Safferman A; Ganguli R; McMeniman M; Borenstein M
    Arch Gen Psychiatry; 2001 Oct; 58(10):965-72. PubMed ID: 11576036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.